Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023)

Elicio Therapeutics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $111.1 million in Q1 2023.

• For the quarter ending Q1 2023, Preferred Stock Liabilities rose 57.67% year-over-year to $111.1 million; the trailing twelve-month figure through Mar 2023 stood at $111.1 million (up 57.67% YoY), and the FY2022 full-year result was $111.1 million, up 57.67% from the prior year.
• Preferred Stock Liabilities for Q1 2023 stood at $111.1 million, roughly flat from $111.1 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $111.1 million in Q4 2022, with the low at $70.4 million in Q4 2021.
• Historically, Preferred Stock Liabilities has averaged $85.8 million across 3 years, with a median of $76.0 million in 2022.
• The largest YoY upside for Preferred Stock Liabilities was 57.67% in 2022 against a maximum downside of 57.67% in 2022.
• Elicio Therapeutics' Preferred Stock Liabilities stood at $70.4 million in 2021, then soared by 57.67% to $111.1 million in 2022, then changed by 0.0% to $111.1 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $111.1 million (Q1 2023), $111.1 million (Q4 2022), and $80.4 million (Q3 2022), per Business Quant data.